This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC
Arsela Prelaj, et al.. Nature Medicine, 2026.
DOI: 10.1038/s41591-026-04488-2
-
Detection and characterization of hepatocellular carcinoma using cfDNA fragmentomes
Hope Orjuela, et al.. Cell Press Blue, 2026.
DOI: 10.1016/j.cpblue.2026.100086
Weekly News Brief: September 21–25, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of September 21–25, 2026.
This week’s brief covers a clinical-data model that sharpened physicians' immunotherapy predictions in advanced NSCLC, and a blood-based fragmentome classifier that caught more liver cancers than alpha-fetoprotein.
To learn more about I3LUNG, read "Decision Support Tool Sharpens Physician Immunotherapy Predictions in Advanced NSCLC," or see the source report in Nature Medicine.
For more information on DELFI, read "Genome-Wide cfDNA Fragmentome Classifier Outperforms AFP for HCC Detection," or see the source report in Cell Press Blue.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.